Novavax Stock News

The European Union''s drug regulator on Monday approved use of the COVID-19 vaccine from U.S.-based Novavax in people 18 years and older, paving the way for a fifth coronavirus shot in the region as the Omicron coronavirus variant spreads. Data from two large studies showed the vaccine has an efficacy of around 90%, the European Medicines Agency (EMA) said, adding that there was currently limited data on its efficacy against some variants of concern, including Omicron.

Get the latest Breaking News Alerts from France 24 in real time on Facebook and Twitter: @BreakingF24

Novavax is expected to start delivering its COVID-19 vaccines to the European Union in the first quarter of 2022, an EU source said, as experts for the region''s drug regulator met on Monday to decide whether to approve the shot.

Novavax is expected to start delivering its COVID-19 vaccines to the European Union in the first quarter of 2022, an EU source said, as experts for the region''s drug regulator met on Monday to decide whether to approve the shot.

Results from clinical trials released in June showed 90.4% efficacy against the disease, and 100% efficacy against severe to moderate cases.

Read more about Novavax is expected to start delivering COVID-19 shots to EU in Q1 2022 - EU source on Devdiscourse

This will be the fifth Covid-19 vaccine approved for use in the European Union.

Novavax, Inc. (NASDAQ:NVAX) with the stream of 11.49% also noticed, India KE Holdings Inc. (NYSE:BEKE) encountered a rapid change of 5.73% in the last hour of Fridays trading session. Novavax, The post Glistening Stocks Review: Novavax, Inc. (NASDAQ:NVAX), KE Holdings Inc. (NYSE:BEKE) appeared first on Stocks Equity .

The World Health Organisation (WHO) has approved the Covovax vaccine for emergency use listing (EUL), elevating to nine the number of immunisations approved to fight the COVID-19 pandemic. The vaccine is produced by the Serum Institute of India, under licence from Novavax, and will now be part of the COVAX facility portfolio, boosting efforts to []

SAN FRANCISCO, Dec. 18, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now .

Novavax says it currently is testing how the shots will hold up against the omicron variant

The World Health Organization yesterday issued an emergency use listing (EUL) for NVX-CoV2373, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus. The vaccine, named CovovaxTM, is produced by the Serum Institute of India under licence from Novavax. Covovax was assessed under the WHO EUL procedure based on the review of data on quality, safety The post COVID: Covovax gets WHO emergency approval appeared first on Gulf Insider .

Related Stocks: PXD , FTV , UTZ , EXPE , TWTR , CMI , NVAX , RYAN , ALNY , FOUR , EPAM , DISCA , WYNN , AVLR , AGIO , SPG , PINS , WING ,

NEW ORLEANS, Dec. 17, 2021 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

The Novavax COVID-19 vaccine known as CovavaxTM has been granted an emergency use authorisation from the World Health Organisation.